Director/PDMR Shareholding

RNS Number : 7062C

Renalytix AI PLC

22 June 2021

 

Renalytix AI plc 

("Renalytix" or the "Company")

Director/PDMR Dealing

The Company was informed that today, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 113.5 pence per share.

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx
2	Reason for the notification
a)	Position/status	Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix AI plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of  £0.0025 each
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Sale of shares
c)	Currency	GBP
d)	Price(s) and volume(s)
			Price(s)	Volume(s)
			11.352941	17,000
e)	Aggregated information
	- Aggregated volume	17,000
	- Price	£192,999.99
f)	Date of the transaction	18 June 2021
g)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHDKBBPCBKKPAB